PDF(Pubmed)
Abstract：
OBJECTIVE: To investigate the psychosocial burden in children and adolescents with juvenile rheumatic diseases during the COVID-19 pandemic.
METHODS: As part of the multicentre observational KICK-COVID study linked to the National Pediatric Rheumatology Database, adolescents < 21 years and parents of children < 12 years with rheumatic diseases answered questions on perceptions of health risk (PHR) due to SARS-CoV2, stress, well-being (WHO-5) and symptoms of depression (PHQ-9) and anxiety (GAD-7). Data were collected at routine visits from June to December 2021 and assessed for association with demographic and clinical parameters, treatment and patient-reported outcomes by multivariable regression analyses.
RESULTS: Data from 1356 individuals (69% female, 50% adolescents) were included. Median PHR on a numeric rating scale (NRS, 0-10) was 4 (IQR 2-6), median perceived stress was 3 (IQR 1-6). Adolescents reported a worse well-being with a significantly lower median WHO-5-score (60, IQR 40-76) than parents reported for their children < 12 years (80, IQR 68-84). Moderate to severe symptoms of depression and anxiety were reported by 14.3% and 12.3% of the adolescents, respectively. PHR was significantly higher in patients with systemic lupus erythematosus, methotrexate or biologic disease-modifying anti-rheumatic drug therapy than in patients without these characteristics, whereas lower WHO-5 or higher PHQ-9 or GAD-7 scores were only associated with poorer patient-reported health status and physical functioning.
CONCLUSIONS: The perception of health risk due to SARS-CoV2 infection was not paralleled by an impairment of mental health, which were, however, significantly correlated with self-rated health status and functional capacity, highlighting the importance of patient-reported outcome assessment.
BACKGROUND: German Clinical Trials Register (DRKS), no. DRKS00027974. Registered on 27th of January 2022.
METHODS: As part of the multicentre observational KICK-COVID study linked to the National Pediatric Rheumatology Database, adolescents < 21 years and parents of children < 12 years with rheumatic diseases answered questions on perceptions of health risk (PHR) due to SARS-CoV2, stress, well-being (WHO-5) and symptoms of depression (PHQ-9) and anxiety (GAD-7). Data were collected at routine visits from June to December 2021 and assessed for association with demographic and clinical parameters, treatment and patient-reported outcomes by multivariable regression analyses.
RESULTS: Data from 1356 individuals (69% female, 50% adolescents) were included. Median PHR on a numeric rating scale (NRS, 0-10) was 4 (IQR 2-6), median perceived stress was 3 (IQR 1-6). Adolescents reported a worse well-being with a significantly lower median WHO-5-score (60, IQR 40-76) than parents reported for their children < 12 years (80, IQR 68-84). Moderate to severe symptoms of depression and anxiety were reported by 14.3% and 12.3% of the adolescents, respectively. PHR was significantly higher in patients with systemic lupus erythematosus, methotrexate or biologic disease-modifying anti-rheumatic drug therapy than in patients without these characteristics, whereas lower WHO-5 or higher PHQ-9 or GAD-7 scores were only associated with poorer patient-reported health status and physical functioning.
CONCLUSIONS: The perception of health risk due to SARS-CoV2 infection was not paralleled by an impairment of mental health, which were, however, significantly correlated with self-rated health status and functional capacity, highlighting the importance of patient-reported outcome assessment.
BACKGROUND: German Clinical Trials Register (DRKS), no. DRKS00027974. Registered on 27th of January 2022.
摘要：
目的：调查COVID-19大流行期间青少年风湿性疾病的心理社会负担。
方法：作为与国家小儿风湿病数据库相关的多中心观察性KICK-COVID研究的一部分，<21岁的青少年和<12岁的风湿性疾病儿童的父母回答了有关SARS-CoV2，压力，健康（WHO-5）和抑郁症（PHQ-9）和焦虑（GAD-7）的症状。在2021年6月至12月的常规访视中收集数据，并评估其与人口统计学和临床参数的相关性。通过多变量回归分析治疗和患者报告的结果。
结果：数据来自1356名个体（69％为女性，包括50％的青少年）。数字评定量表上的PHR中位数(NRS，0-10）为4（IQR2-6），中位感知压力为3(IQR1-6).青少年报告的幸福感较差，WHO-5分中位数（60，IQR40-76）明显低于父母报告的<12岁儿童（80，IQR68-84）。14.3％和12.3％的青少年报告了中度至重度的抑郁和焦虑症状，分别。系统性红斑狼疮患者的PHR显著增高，甲氨蝶呤或生物疾病缓解抗风湿药物治疗比没有这些特征的患者，而较低的WHO-5或较高的PHQ-9或GAD-7评分仅与患者报告的健康状况和身体功能较差相关.
结论：对SARS-CoV2感染引起的健康风险的看法并不与精神健康受损相提并论，是，然而,与自我评估的健康状况和功能能力显着相关，强调患者报告结局评估的重要性。
背景：德国临床试验注册（DRKS），不。DRKS00027974。2022年1月27日注册。
方法：作为与国家小儿风湿病数据库相关的多中心观察性KICK-COVID研究的一部分，<21岁的青少年和<12岁的风湿性疾病儿童的父母回答了有关SARS-CoV2，压力，健康（WHO-5）和抑郁症（PHQ-9）和焦虑（GAD-7）的症状。在2021年6月至12月的常规访视中收集数据，并评估其与人口统计学和临床参数的相关性。通过多变量回归分析治疗和患者报告的结果。
结果：数据来自1356名个体（69％为女性，包括50％的青少年）。数字评定量表上的PHR中位数(NRS，0-10）为4（IQR2-6），中位感知压力为3(IQR1-6).青少年报告的幸福感较差，WHO-5分中位数（60，IQR40-76）明显低于父母报告的<12岁儿童（80，IQR68-84）。14.3％和12.3％的青少年报告了中度至重度的抑郁和焦虑症状，分别。系统性红斑狼疮患者的PHR显著增高，甲氨蝶呤或生物疾病缓解抗风湿药物治疗比没有这些特征的患者，而较低的WHO-5或较高的PHQ-9或GAD-7评分仅与患者报告的健康状况和身体功能较差相关.
结论：对SARS-CoV2感染引起的健康风险的看法并不与精神健康受损相提并论，是，然而,与自我评估的健康状况和功能能力显着相关，强调患者报告结局评估的重要性。
背景：德国临床试验注册（DRKS），不。DRKS00027974。2022年1月27日注册。
